Loading...
Loading...
- Qiagen NV QGEN on Monday after-hours reported first-quarter revenue growth of 52% Y/Y to $567.2 million, exceeding prior guidance and beating analyst consensus by $9.68 million.
- Adjusted EPS $0.65 beat analyst consensus of $0.63 and exceeded prior company guidance of $0.60 - $0.62.
- Q1 revenues grew 48% Y/Y at constant exchange rates, faster than previously guided for at least 45%.
- By product category, consumables and related revenues grew 53% to $498 million, while instrument sales rose 49% to $69 million.
- By customer class, molecular diagnostics revenues increased 59% to $279 million, while life sciences revenues spiked 47% to $288 million.
- Qiagen CEO Thierry Bernard noted that the company achieved 16% CER growth in sales of non-COVID-19-related products that represented 64% of total Q1 sales, or $364 million.
- Demand for products used in COVID-19 testing, which had $203 million in sales, was similar to the fourth quarter of 2020.
- "We are pleased with trends showing that research laboratories around the world are increasingly returning to work, and clinical labs are moving beyond COVID testing," Bernard said.
- The company exited Q1 with $787.8 million in cash and equivalents and generated $128.6 million in operating cash flow.
- Guidance: Qiagen confirmed the FY21 forecast for adjusted earnings per share of $2.42 to $2.46 and net sales growth of 18% to 20% at constant exchange rates.
- Price Action: QGEN shares are trading higher by 0.42% at $47.82 in the premarket session on the last check Tuesday.
Loading...
Loading...
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Date | ticker | name | Actual EPS | EPS Surprise | Actual Rev | Rev Surprise |
---|
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in